Updated Mar 8
A healthcare worker holds up three syringes with clear medicine
To Booster or Not: Scientists and Regulators Debate
President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.
To Booster or Not: Scientists and Regulators Debate
To Booster or Not: Scientists and Regulators Debate

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

Neutralizing antibody
Learn About Sero-Surveillance During the COVID-19 Pandemic
Using Sero-Surveillance to Combat the COVID-19 Pandemic
The Scientist Creative Services Team and Bio-Rad Laboratories | Feb 7, 2022
Immunoassays for detecting, tracking, and testing SARS-CoV-2 antibody responses
COVID-19, SARS-CoV-2, coronavirus, pandemic, vaccine, vaccine trials, combination, mix and match, immunity, antibodies, T cells, Pfizer, Moderna, AstraZeneca, clinical trials
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
regeneron monoclonal antibody sars-cov-2 covid-19 pandemic coronavirus neutralization b.1.351 variant south africa REGN10987 casirivimab and REGN10933 imdevimab
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
biogen biobank coronavirus covid-19 sars-cov-2 pandemic superspreader superspreading event antibodies neutralizing titers
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research
Claire Jarvis | May 19, 2020
A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.
Dengue Infection Impairs Immune Defense Against Zika
Catherine Offord | Aug 18, 2017
A memory B cell response to Zika virus in dengue-infected patients produced antibodies that were poorly neutralizing in vitro and instead enhanced infection.
Unique Antibodies Open Path Toward New HIV Vaccines
Amanda B. Keener | Jan 27, 2017
A family of broadly neutralizing antibodies from a chronically infected donor provides a schematic for designing vaccines and treatments that target multiple strains of the virus.
Culprit for Antibody Blockade Identified
Amanda B. Keener | Oct 21, 2016
Type I interferon organizes several immune mechanisms to suppress B cell responses to a chronic viral infection.
Accelerating Antibody Discovery
Nicholette Zeliadt | May 1, 2014
Techniques for faster discovery and isolation of human monoclonal antibodies